MMAE Antibody Drug Conjugate (ADC) ELISA Kit
MMAE ADC ELISA refers to an enzyme-linked immunosorbent assay (ELISA) designed to detect and quantify antibody–drug conjugates (ADCs) carrying monomethyl auristatin E (MMAE), a potent cytotoxic agent. MMAE is commonly conjugated to monoclonal antibodies to selectively deliver the drug to tumor cells, minimizing systemic toxicity. The MMAE ADC ELISA measures the concentration of the intact conjugate in biological samples, such as plasma or serum, providing critical pharmacokinetic and pharmacodynamic data for drug development.
In research, MMAE ADC ELISA is used to evaluate the pharmacokinetics, stability, and bioavailability of MMAE-based ADCs in preclinical and clinical studies. Researchers monitor how the ADC circulates, its clearance rate, and the potential release of MMAE over time. These measurements are essential for optimizing dosing regimens, understanding the relationship between exposure and therapeutic efficacy, and assessing safety profiles in animal models and early-phase human trials.
Clinically, MMAE ADC ELISA supports therapeutic monitoring and drug development by providing quantitative data on circulating ADC levels. It helps guide dosing schedules, assess patient exposure, and monitor potential toxicity, ensuring effective and safe treatment. Additionally, the assay is a key tool for regulatory compliance, linking preclinical pharmacology and pharmacokinetics to clinical application in targeted cancer therapy.
This MMAE Antibody Drug Conjugate (ADC) ELISA Kit is manufactured in USA by Eagle Biosciences.
Related products
